Pamidronate-induced kidney injury in a patient with metastatic breast cancer

American Journal of the Medical Sciences

Volumn 338, Issue 3, 2009, Pages 225-228

  Nagahama, Masahiko ^a   Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Breast cancer; Focal segmental glomerulosclerosis; Pamidronate induced kidney injury

Indexed keywords

ALBUMIN; CALCIUM; CHOLESTEROL; CREATININE; ESOMEPRAZOLE; EXEMESTANE; HEMOGLOBIN; NITROGEN; PAMIDRONIC ACID; UREA; VALSARTAN; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE;

AGED; ANAMNESIS; APOPTOSIS; ARTICLE; BONE METASTASIS; BREAST CANCER; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; ERYTHROCYTE COUNT; FEMALE; FEMUR SHAFT; FIBROSING ALVEOLITIS; FOCAL GLOMERULOSCLEROSIS; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; KIDNEY BIOPSY; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; LABORATORY TEST; LEUKOCYTE COUNT; MICROSCOPY; MITOCHONDRIAL MEMBRANE; NEPHROSIS; OSTEOLYSIS; PERCUTANEOUS BIOPSY; PODOCYTE; PROGNOSIS; PROTEIN URINE LEVEL; PROTEINURIA; UREA NITROGEN BLOOD LEVEL; VITAL SIGN; BONE TUMOR; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METASTASIS; MITOCHONDRION; PATHOLOGY; REVIEW;

AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; MITOCHONDRIA;

EID: 70349234673     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318184e741     Document Type: Article

References (24)

1. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-4057
2. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16: 2038-2044
3. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow- up of two randomized, placebo-controlled trials. Cancer 2000;88: 1082-1090 (Pubitemid 30127670)
4. Hultborn R, Gundersen S, Ryden S, et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo- controlled multicenter study. Anticancer Res 1999;19: 3383-3392 (Pubitemid 30000192)
5. Thammasitboon S, Thammasitboon S. A critical appraisal of a systematic review: Sokol J, Jacob SE, Bohn D: inhaled nitric oxide for acute hypoxemic respiratory failure in children and adults. Cochrane Database Syst Rev 2003 (1): CD002787.
6. Pediatr Crit Care Med 2005; 6:340-343
7. Ross JR, Saunders Y, Edmonds PM, et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003;327:469. (Pubitemid 37056193)
8. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001;12:1164-1172 (Pubitemid 32472629)
9. Sauter M, Jülg B, Porubsky S, et al. Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept? Am J Kidney Dis 2006;47:1075-1080
10. Barri YM, Munshi NC, Sukumalchantra S, et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 2004; 65:634-641 (Pubitemid 38130659)
11. Kunin M, Kopolovic J, Avigdor A, et al. Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient. Nephrol Dial Transplant 2004;19:723-726 (Pubitemid 38263136)
12. Johnston AD. Pathology of metastatic tumors in bone. Clin Orthop Relat Res 1970;73:8-32.
13. Coleman RE, Rubens RD. Bone metastases and breast cancer. Cancer Treat Rev 1985;12:251-270
14. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000;15:2211-2221 (Pubitemid 30800836)
15. Senaratne SG, Pirianov G, Mansi JL, et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459-1468 (Pubitemid 30175914)
16. Tralongo P, et al. Safety of long-term administration of bisphosphonates in elderly cancer patients. Oncology 2004;67:112-116 (Pubitemid 39482678)
17. Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999;21:389-406. (Pubitemid 29520900)
18. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-387 (Pubitemid 33759002)
19. Jaffe JA, Kimmel PL. Chronic nephropathies of cocaine and heroin abuse: a critical review. Clin J Am Soc Nephrol 2006;1:655-667
20. Korbet SM. Primary focal segmental glomerulosclerosis. J Am Soc Nephrol 1998;9:1333-1340
21. Adami S, Zamberlan N. Adverse effects of bisphosphonates. A comparative review. Drug Saf 1996;14:158-170
22. Braun JP, Rico AG, Benard P, et al. [Urinary gamma-glutamyl transferase in renal toxicology of the rat. Bases of its use and significance in acute mercurial nephritis.] Toxicology 1978;11: 73-82.
23. Shreedhara M, Fenves AZ, Benavides D, et al. Reversibility of pamidronate-associated glomerulosclerosis. Proc (Bayl Univ Med Cent) 2007;20:249-253
24. Patel SS, Kimmel PL, Singh A. New clinical practice guidelines for chronic kidney disease: a framework for K/DOQI. Semin Nephrol 2002;22:449-458 (Pubitemid 35355717)